Genotypic challenges in implementing broadly neutralizing antibody-based long-acting HIV-1 therapies.

Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.

Related documents

• Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial#260685
• HIV-2 infection as a comparative lens for functional HIV-1 remission.#152256
• Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC#283047
• Phase I - Pre-Radical Prostatectomy RTVP-1 Gene Therapy for Prostate Cancer#1173917
• Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting#811551